Experienced in HIV/AIDS

Eduardo Sprinz

Rio Grande, RS, BR 
Experienced in HIV/AIDS
Rio Grande, RS, BR 
OverviewLocationsClinical Research

Overview

Eduardo Sprinz practices in Rio Grande, Brazil. Mr. Sprinz is rated as an Experienced expert by MediFind in the treatment of HIV/AIDS. His top areas of expertise are Severe Acute Respiratory Syndrome (SARS), Pneumonia, COVID-19, and HIV/AIDS.

His clinical research consists of co-authoring 63 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 30 articles and participated in 1 clinical trial in the study of HIV/AIDS.

Gender
Male

Locations

Rio Grande, RS, Brazil
Other Locations
Porto Alegre, RS, Brazil

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Study to Evaluate the Efficacy and Safety of CardiolRx™ in Patients With COVID-19 and Cardiovascular Disease or Risk Factors A Double-blind, Placebo-controlled Trial
Study to Evaluate the Efficacy and Safety of CardiolRx™ in Patients With COVID-19 and Cardiovascular Disease or Risk Factors A Double-blind, Placebo-controlled Trial
Enrollment Status: Terminated
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drug: Cannabidiol, Pharmaceutically Produced with < 5 ppm THC
Study Phase: Phase 2/Phase 3
A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease
A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease
Enrollment Status: Completed
Publish Date: September 23, 2024
Intervention Type: Biological, Drug
Study Drugs: Otilimab, Standard of Care
Study Phase: Phase 2
Impact of a Dolutegravir-based Regimen on Early Mortality of Severely Immunocompromised AIDS Patients
Impact of a Dolutegravir-based Regimen on Early Mortality of Severely Immunocompromised AIDS Patients
Enrollment Status: Completed
Publish Date: December 14, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir, Efavirenz-based regimens
Study Phase: Phase 2/Phase 3
Randomized Master Protocol for Immune Modulators for Treating COVID-19
Randomized Master Protocol for Immune Modulators for Treating COVID-19
Enrollment Status: Completed
Publish Date: September 25, 2023
Intervention Type: Drug
Study Drugs: Infliximab, Abatacept, Remdesivir, Cenicriviroc
Study Phase: Phase 3
A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) for the Prevention of SARS-CoV-2- Mediated COVID-19 in Participants Aged 12 Years and Older
A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) for the Prevention of SARS-CoV-2- Mediated COVID-19 in Participants Aged 12 Years and Older
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
Phase 3, Randomized, Placebo-Controlled, Efficacy and Safety Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS).
Phase 3, Randomized, Placebo-Controlled, Efficacy and Safety Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS).
Enrollment Status: Completed
Publish Date: April 18, 2023
Intervention Type: Drug
Study Drug: VERU-111
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
Enrollment Status: Completed
Publish Date: July 28, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants With COVID-19 Pneumonia (ANEMONE)
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants With COVID-19 Pneumonia (ANEMONE)
Enrollment Status: Completed
Publish Date: June 06, 2022
Intervention Type: Drug
Study Drug: M5049
Study Phase: Phase 2
View 7 Less Clinical Trials

63 Total Publications

Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil.
Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil.
Journal: Mayo Clinic proceedings. Innovations, quality & outcomes
Published: July 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Sprinz's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile